Tetrahydrofuran

Tetrahydrofuran

SCHEMBL377183

C1CCOC1.NCCCN

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.53
KEAP1 Q14145 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NFKB1 P19838 1/20 0.38
TSHR P16473 3/20 0.35
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA3 P07451 2/20 0.35
CA4 P22748 2/20 0.35
CA6 P23280 2/20 0.35
CA5A P35218 2/20 0.35
CA7 P43166 2/20 0.35
CA9 Q16790 2/20 0.35
CA14 Q9ULX7 2/20 0.35
CA5B Q9Y2D0 2/20 0.35
LMNA P02545 2/20 0.35
BLM P54132 2/20 0.35
DNM1 Q05193 1/20 0.35
TTR P02766 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrahydrofuran SCHEMBL28233745 0.86 ALDH1A1 (0.61) ALDH1A1KEAP1SMN1; SMN2TSHRTTR
Tetrahydrofuran SCHEMBL11751241 0.86
Tetrahydrofuran SCHEMBL3836712 0.84 ALDH1A1 (0.38) ALDH1A1KEAP1SMN1; SMN2
Tetrahydrofuran SCHEMBL9015780 0.83 DNM1 (0.46) ALDH1A1KEAP1SMN1; SMN2NFKB1TSHR
Tetrahydrofuran SCHEMBL28585403 0.83 DNM1 (0.46) ALDH1A1KEAP1SMN1; SMN2NFKB1TSHR
Tetrahydrofuran SCHEMBL1728990 0.83 DNM1 (0.46) ALDH1A1KEAP1SMN1; SMN2NFKB1TSHR
Ethylenediamine SCHEMBL11754311 0.83 ALDH1A1 (0.57) ALDH1A1KEAP1SMN1; SMN2TSHRTTR
Tetrahydrofuran SCHEMBL288894 0.83 TDP1 (0.40) ALDH1A1KEAP1SMN1; SMN2TSHRCA12
Oxirane SCHEMBL28217784 0.82
Tetrahydrofuran SCHEMBL8250456 0.81 DNM1 (0.43) ALDH1A1KEAP1SMN1; SMN2TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3558981-A1 PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS Orion Corporation (FI) 2019-10-30 EP claimed
WO-2018115591-A1 PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS ORION CORPORATION (FI) 2018-06-28 WO claimed
WO-2024126773-A1 IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-06-20 WO disclosed
WO-2024038131-A1 INHIBITORS OF MYELOPEROXIDASE ASTRAZENECA AB (SE) 2024-02-22 WO disclosed
EP-4313980-A1 LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS Fedora Pharmaceuticals Inc. (CA) 2024-02-07 EP disclosed
WO-2020054670-A1 NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME 科研製薬株式会社 2020-03-19 WO disclosed
WO-2020054657-A1 NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME 科研製薬株式会社 2020-03-19 WO disclosed
CN-110240616-A Three biaryl monophosphorus ligands, their preparation method and the purposes in catalyzed coupling reaction 东莞市均成高新材料有限公司 2019-09-17 CN disclosed
US-20190192475-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS CYMABAY THERAPEUTICS, INC. 2019-06-27 US disclosed
CN-109843296-A Hepatitis B antiviral agent 英安塔制药有限公司 2019-06-04 CN disclosed
EP-1791812-B1 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS JANSSEN PHARMACEUTICA NV (BE) 2015-11-04 EP disclosed
WO-2005042478-A2 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-05-12 WO disclosed
US-20040162352-A1 Treating syndrome X with substituted tetralins and indanes JANSSEN PHARMACEUTICA N.V. (BE) 2004-08-19 US disclosed
EP-1444232-A1 PHENYL SUBSTITUTED TRIAZOLES AND THEIR USE AS SELECTIVE INHIBORS OF AKL5 KINASE SMITHKLINE BEECHAM CORPORATION (US) 2004-08-11 EP disclosed
WO-2004037779-A1 SUBSTITUTED TETRALINS AND INDANES AND THEIR USE JANSSEN PHARMACEUTICA, N.V. (BE) 2004-05-06 WO disclosed
WO-2004037778-A1 SUBSTITUTED TETRALINS AND INDANES JANSSEN PHARMACEUTICA, N.V. (BE) 2004-05-06 WO disclosed
WO-2004037777-A1 TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND INDANES JANSSEN PHARMACEUTICA, N.V. (BE) 2004-05-06 WO disclosed
WO-2003042211-A1 PHENYL SUBSTITUTED TRIAZOLES AND THEIR USE AS SELECTIVE INHIBORS OF AKL5 KINASE SMITHKLINE BEECHAM CORPORATION (US) 2003-05-22 WO disclosed
EP-0952998-A1 POLYMERIZATION OF ETHYLENE E.I. DU PONT DE NEMOURS AND COMPANY (US) 1999-11-03 EP disclosed
WO-1998030610-A1 POLYMERIZATION OF ETHYLENE E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190192475-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS PPARA, PPARG, PPARD ALDH1A1 1562/4885KEAP1 1408/4885SMN1; SMN2 4883/4885
US-20040162352-A1 Treating syndrome X with substituted tetralins and indanes PPARG, PPARA, PPARD ALDH1A1 2145/4885KEAP1 1706/4885SMN1; SMN2 3039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.